FLT PET-CT in evaluation of treatment response

Indian Journal of Nuclear Medicine

Volumn 29, Issue 2, 2014, Pages 65-73

  Sanghera, Bal ^a   Wong, Wai ^a   Sonoda, Luke ^a   Beynon, Gwen ^a   Makris, Andreas ^a   Woolf, David ^a   Ardeshna, Kirit ^a,b  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

positron emission tomography; predict; response; review; treatment

Indexed keywords

3' FLUOROTHYMIDINE F 18; BEVACIZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; GEFITINIB; IRINOTECAN; KI 67 ANTIGEN; PREDNISONE; RITUXIMAB; SUNITINIB; TICILIMUMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTIANGIOGENIC THERAPY; B CELL LYMPHOMA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG WITHDRAWAL; ESOPHAGUS CANCER; GERM CELL TUMOR; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; KIDNEY CANCER; LARGE CELL LYMPHOMA; LARYNX CANCER; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MELANOMA; META ANALYSIS; OROPHARYNX CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECTUM CANCER; REFERENCE DATABASE; RELATIVE BIOLOGIC EFFECTIVENESS; REVIEW; SOFT TISSUE SARCOMA; STOMACH CANCER; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84898777342     PISSN: 09723919     EISSN: 09740244     Source Type: Journal    
DOI: 10.4103/0972-3919.130274     Document Type: Review

References (61)

1. Ben-Haim S, Ell P. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med 2009;50:188-99.
2. Weber WA. Assessing tumor response to therapy. J Nucl Med 2009;50:1S-10S.
3. Lopci E, Fanti S. Molecular imaging in oncology. Recent Results Cancer Res 2013;187:371-400.
4. Chalkidou A, Landau DB, Odell EW, Cornelius VR, O'Doherty MJ, Marsden PK. Correlation between Ki-67 immunohistochemistry and 18F-Fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. Eur J Cancer 2012;48:3499-513.
5. Krohn KA, Mankoff DA, Eary JF. Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol 2001:96S-103S.
6. Hicks RJ. The role of PET in monitoring therapy. Cancer Imaging 2005;5:51-7.
7. Yang Y, Czernin J. Contribution of imaging to cancer care costs. J Nucl Med 2011;52:86S-92S.
8. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol 2007;25:4714-21.
9. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, et al. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med 2012;53:29-36.
10. Schiepers C, Dahlbom M, Chen W, Cloughesy T, Czernin J, Phelps ME, et al. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med 2010;51:720-7.
11. Wardak M, Schiepers C, Dahlbom M, Cloughesy T, Chen W, Satyamurthy N, et al. Discriminant analysis of 8 F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clin Cancer Res 2011;17:6553-62.
12. Been LB, Hoekstra HJ, Suurmeijer AJ, Jager PL, van der Laan BF, Elsinga PH. [18F] FLT-PET and [18F] FDG-PET in the evaluation of radiotherapy for laryngeal cancer. Oral Oncol 2009;45:e211-5.
13. Menda Y, Boles Ponto LL, Dornfeld KJ, Tewson TJ, Watkins GL, et al. Kinetic analysis of 3'-deoxy-3'-(18) F-fluorothymidine ((18) F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. J Nucl Med 2009;50:1028-35.
14. Kishino T, Hoshikawa H, Nishiyama Y, Yamamoto Y, Mori N. Usefulness of 3'-deoxy-3'-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer. J Nucl Med 2012;53:1521-7.
15. Troost EG, Bussink J, Hoffmann AL, Boerman OC, Oyen WJ, Kaanders JH. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med 2010;51:866-74.
16. Hoeben BA, Troost EG, Span PN, van Herpen CM, Bussink J, Oyen WJ, et al. 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med 2013;54:532-40.
17. Yue J, Chen L, Cabrera AR, Sun X, Zhao S, Zheng F, et al. Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: A pilot clinical study. J Nucl Med 2010;51:528-34.
18. Withers HR, Taylor JM. Critical volume model. Int J Radiat Oncol Biol Phys 1993;25:151-2.
19. Sohn HJ, Yang YJ, Ryu JS, Oh SJ, Im KC, Moon DH, et al. [18F] Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 2008;14:7423-9.
20. Zander T, Scheffler M, Nogova L, Kobe C, Engel-Riedel W, Hellmich M, et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F] fluorodeoxyglucose and [(18) F] fluorothymidine positron emission tomography. J Clin Oncol 2011;29:1701-8.
21. Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, et al. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res 2011;17:3304-15.
22. Kahraman D, Scheffler M, Zander T, Nogova L, Lammertsma AA, Boellaard, et al. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET. J Nucl Med 2011;52:1871-7.
23. Kobe C, Scheffler M, Holstein A, Zander T, Nogova L, Lammertsma AA, et al. Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. Eur J Nucl Med Mol Imaging 2012;39:1117-27.
24. Yang W, Zhang Y, Fu Z, Sun X, Mu D, Yu J. Imaging proliferation of 18F-FLT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 2012;39:1289-96.
25. Scheffler M, Zander T, Nogova L, Kobe C, Kahraman D, Dietlein M, et al. Prognostic impact of [18F] fluorothymidine and [18F] fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib. PLoS One 2013;8:e53081.
26. Saga T, Koizumi M, Inubushi M, Yoshikawa K, Tanimoto K, Fukumura T, et al. PET/CT with 3'-deoxy-3'-[18F] fluorothymidine for lung cancer patients receiving carbon-ion radiotherapy. Nucl Med Commun 2011;32:348-55.
27. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: A pilot study in breast cancer patients with 3'-deoxy-3'-[18F] fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007;34:1339-47.
28. Contractor KB, Kenny LM, Stebbing J, Rosso L, Ahmad R, Jacob J. [18F]-3'Deoxy 3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin Cancer Res 2011;17:7664-72.
29. Lubberink M, Direcks W, Emmering J, van Tinteren H, Hoekstra OS, van der Hoeven JJ. Validity of simplified 3'-deoxy-3'-[(18) f] fluorothymidine uptake measures for monitoring response to chemotherapy in locally advanced breast cancer. Mol Imaging Biol 2012;14:777-82.
30. Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder HA. Molecular imaging of proliferation and glucose utilization: Utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol 2011;18:3316-23.
31. Liu G, Jeraj R, Vanderhoek M, Perlman S, Kolesar J, Harrison M. Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clin Cancer Res 2011;17:7634-44.
32. Wieder HA, Geinitz H, Rosenberg R, Lordick F, Becker K, Stahl A. PET imaging with [18F] 3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 2007;34:878-83.
33. Dehdashti F, Grigsby PW, Myerson RJ, Nalbantoglu I, Ma C, Siegel BA. Positron emission tomography with [(18) f]-3'-deoxy-3'fluorothymidine (flt) as a predictor of outcome in patients with locally advanced resectable rectal cancer: A Pilot Study. Mol Imaging Biol 2013;15:106-13.
34. Been LB, Suurmeijer AJ, Elsinga PH, Jager PL, van Ginkel RJ, Hoekstra HJ. 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas. J Nucl Med 2007;48:367-72.
35. Benz MR, Czernin J, Allen-Auerbach MS, Dry SM, Sutthiruangwong P, Spick C, et al. 3'-deoxy-3'-[18F] fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: A pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response. Cancer 2012;118:3135-44.
36. Pfannenberg C, Aschoff P, Dittmann H, Mayer F, Reischl G, von Weyhern C, et al. PET/CT with 18F-FLT: Does it improve the therapeutic management of metastatic germ cell tumors? J Nucl Med 2010;51:845-53.
37. Herrmann K, Wieder HA, Buck AK, Schöffel M, Krause BJ, Fend F, et al. Early response assessment using 3'-deoxy-3'-[18F] fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 2007;13:3552-8.
38. Herrmann K, Buck AK, Schuster T, Junger A, Wieder HA, Graf N, et al. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med 2011;52:690-6.
39. Herrmann K, Buck AK, Schuster T, Rudelius M, Wester HJ, Graf N, et al. A pilot study to evaluate 3'-deoxy-3'-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma. J Nucl Med 2011;52:1898-902.
40. Vanderhoek M, Juckett MB, Perlman SB, Nickles RJ, Jeraj R. Early assessment of treatment response in patients with AML using [(18) F] FLT PET imaging. Leuk Res 2011;35:310-6.
41. Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, et al. Imaging of CTLA4 blockade-induced cell replication with (18) F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med 2010;51:340-6.
42. Aarntzen EH, Srinivas M, De Wilt JH, Jacobs JF, Lesterhuis WJ, Windhorst AD, et al. Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F] FLT) PET imaging. Proc Natl Acad Sci USA 2011;108:18396-9.
43. Dimitrakopoulou-Strauss A, Strauss LG. The role of F-FLT in cancer imaging: Does it really reflect proliferation? Eur J Nucl Med Mol Imaging 2008;35:523-6.
44. Shields AF, Lawhorn-Crews JM, Briston DA, Zalzala S, Gadgeel S, Douglas KA, et al. Analysis and reproducibility of 3'-Deoxy-3'-[18F] fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer. Clin Cancer Res 2008;14:4463-8.
45. De Langen AJ, Klabbers B, Lubberink M, Boellaard R, Spreeuwenberg MD, Slotman BJ, et al. Reproducibility of quantitative 18F-3'-deoxy-3'- fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging 2009;36:389-95.
46. Cheebsumon P, van Velden FH, Yaqub M, Frings V, de Langen AJ, Hoekstra OS, et al. Effects of image characteristics on performance of tumor delineation methods: A test-retest assessment. J Nucl Med 2011;52:1550-8.
47. Bading JR, Shields AF. Imaging of cell proliferation: Status and prospects. J Nucl Med 2008;49:64S-80S.
48. Salskov A, Tammisetti VS, Grierson J, Vesselle H. FLT: Measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F] fluorothymidine. Semin Nucl Med 2007;37:429-39.
49. Barwick T, Bencherif B, Mountz JM, Avril N. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: A comprehensive evaluation. Nucl Med Commun 2009;30:908-17.
50. Plotnik DA, Emerick LE, Krohn KA, Unadkat JD, Schwartz JL. Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells. J Nucl Med 2010;51:1464-71.
51. Vanderhoek M, Perlman SB, Jeraj R. Impact of the definition of peak standardized uptake value on quantification of treatment response. J Nucl Med 2012;53:4-11.
52. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122S-50S.
53. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: Version 1.0. Eur J Nucl Med Mol Imaging 2010;37:181-200.
54. Ware RE, Hicks RJ. Doing more harm than good? Do systematic reviews of PET by health technology assessment agencies provide an appraisal of the evidence that is closer to the truth than the primary data supporting its use? J Nucl Med 2011;52:64S-73S.
55. Schwaiger M, Wester HJ. How many PET tracers do we need? J Nucl Med 2011;52:36S-41S.
56. De Saint-Hubert M, Brepoels L, Mottaghy FM. Can evaluation of targeted therapy in oncology be improved by means of 18F-FLT? J Nucl Med 2010;51:1499-500.
57. Kaira K, Oriuchi N, Sunaga N, Ishizuka T, Shimizu K, Yamamoto N. A systemic review of PET and biology in lung cancer. Am J Transl Res 2011;3:383-91.
58. De Saint-Hubert M, Bauwens M, Verbruggen A, Mottaghy FM. Apoptosis imaging to monitor cancer therapy: The road to fast treatment evaluation? Curr Pharm Biotechnol 2012;13:571-83.
59. Kalia M. Personalized oncology: Recent advances and future challenges. Metabolism 2013;62:S11-4.
60. McKinley ET, Ayers GD, Smith RA, Saleh SA, Zhao P, Washington MK, et al. Limits of [18F]-FLT PET as a biomarker of proliferation in oncology. PLoS One 2013;8:e58938.
61. Tehrani OS, Shields AF. PET Imaging of proliferation with pyrimidines. J Nucl Med 2013;54:903-12.